June ’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly ’s empagliflozin trial

A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic k …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news